Literature DB >> 2957429

A urine inhibitor of interleukin 1 activity that blocks ligand binding.

P Seckinger, J W Lowenthal, K Williamson, J M Dayer, H R MacDonald.   

Abstract

Urine from febrile patients was found to contain a novel inhibitor of interleukin 1 (IL-1) bioactivity that blocked the specific binding of radioiodinated IL-1 to its receptor in a dose-dependent fashion. Strong inhibition of IL-1 binding was still obtained when cells were preincubated with the inhibitor and washed, thus suggesting that the inhibitor binds to a surface structure (possibly the IL-1 receptor itself). The inhibitor was distinct from IL-1 as determined by both physical parameters (size and antigenicity) and receptor-binding characteristics (apparent affinity and dissociation rate). These data provide evidence for a physiologic regulator of IL-1 activity that functions in vivo via direct interference with ligand binding.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2957429

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  64 in total

Review 1.  Cytokines in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

2.  Glucocorticoid-induced keratinocyte-derived interleukin-1 receptor antagonist(s).

Authors:  S Stosić-Grujicić; M L Lukić
Journal:  Immunology       Date:  1992-02       Impact factor: 7.397

3.  Inhibitor of interleukin-1 alpha and interleukin-1 beta-induced T-cell activation in serum of patients with active Crohn's disease.

Authors:  J Brynskov; M B Hansen; C Reimert; K Bendtzen
Journal:  Dig Dis Sci       Date:  1991-06       Impact factor: 3.199

4.  Tissue-engineered cartilage with inducible and tunable immunomodulatory properties.

Authors:  Katherine A Glass; Jarrett M Link; Jonathan M Brunger; Franklin T Moutos; Charles A Gersbach; Farshid Guilak
Journal:  Biomaterials       Date:  2014-04-22       Impact factor: 12.479

5.  Inhibitory effect and mechanism of mesenchymal stem cells on melanoma cells.

Authors:  J Zhang; L Hou; D Zhao; M Pan; Z Wang; H Hu; J He
Journal:  Clin Transl Oncol       Date:  2017-07-21       Impact factor: 3.405

Review 6.  The role of tumor necrosis factor and interleukin 1 in the immunoinflammatory response.

Authors:  J W Larrick; S L Kunkel
Journal:  Pharm Res       Date:  1988-03       Impact factor: 4.200

7.  Release of interleukin 1 inhibitory activity (contra-IL-1) by human monocyte-derived macrophages infected with human immunodeficiency virus in vitro and in vivo.

Authors:  R M Locksley; S Crowe; M D Sadick; F P Heinzel; K D Gardner; M S McGrath; J Mills
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

8.  Differential interleukin-1 receptor antagonism on pancreatic beta and alpha cells. Studies in rodent and human islets and in normal rats.

Authors:  U Zumsteg; J I Reimers; F Pociot; L Mørch; S Helqvist; M Brendel; R Alejandro; T Mandrup-Poulsen; C A Dinarello; J Nerup
Journal:  Diabetologia       Date:  1993-08       Impact factor: 10.122

9.  Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study.

Authors:  Maren Carstensen; Christian Herder; Mika Kivimäki; Markus Jokela; Michael Roden; Martin J Shipley; Daniel R Witte; Eric J Brunner; Adam G Tabák
Journal:  Diabetes       Date:  2010-02-25       Impact factor: 9.461

10.  Purinergic P2X7 receptors regulate secretion of interleukin-1 receptor antagonist and beta cell function and survival.

Authors:  R Glas; N S Sauter; F T Schulthess; L Shu; J Oberholzer; K Maedler
Journal:  Diabetologia       Date:  2009-04-25       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.